Monoamine neurotransmitter disorders associated with abnormal dopamine metabolism are associated with predominantly neurological phenotypes

Mononeurotransmitter disorders are underrecognised despite many being treatable and pharmacoresponsive and should be considered in those presenting with movement disorder and unexplained cerebral palsy

Treatment strategies should be tailored to the specific neurotransmitter defect with input from the expert neurologist